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Background: Vitamin D receptors have been identified in the spinal cord, nerve roots, dorsal root ganglia and glial
cells, and its genetic polymorphism association with the development of lumbar disc degeneration and herniation
has been documented. Metabolic effects of active vitamin D metabolites in the nucleus pulposus and annulus
fibrosus cells have been studied. Lumbar disc herniation is a process that involves immune and inflammatory cells
and processes that are targets for immune regulatory actions of vitamin D as a neurosteroid hormone. In addition
to vitamin D’s immune modulatory properties, its receptors have been identified in skeletal muscles. It also affects
sensory neurons to modulate pain. In this study, we aim to study the role of vitamin D3 in discogenic pain and
related sensory deficits. Additionally, we will address how post-treatment 25-hydroxy vitamin D3 level influences
pain and sensory deficits severity. The cut-off value for serum 25-hydroxy vitamin D3 that would be efficacious in
improving pain and sensory deficits in lumbar disc herniation will also be studied.
Methods/Design: We will conduct a randomized, placebo-controlled, double-blind clinical trial. Our study
population will include 380 cases with one-level and unilateral lumbar disc herniation with duration of discogenic
pain less than 8 weeks. Individuals who do not have any contraindications, will be divided into three groups
based on serum 25-hydroxy vitamin D3 level, and each group will be randomized to receive either a single-dose
300,000-IU intramuscular injection of vitamin D3 or placebo. All patients will be under conservative treatment.
Pre-treatment and post-treatment assessments will be performed with the McGill Pain Questionnaire and a visual
analogue scale. For the 15-day duration of this study, questionnaires will be filled out during telephone interviews
every 3 days (a total of five times). The initial and final interviews will be scheduled at our clinic. After 15 days,
serum 25-hydroxy vitamin D3 levels will be measured for those who have received vitamin D3 (190 individuals).
Trial registration: Iranian Registry for Clinical Trials ID: IRCT2014050317534N1 (trial registration: 5 June 2014)
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Medical treatment is the first step in therapy for lum-
bar disc herniation (LDH), except for patients who re-
quire immediate surgical decompression. Drugs that are
utilized in treatment of LDH pain and sensory defi-
cits include muscle relaxants [1-3], analgesics [1,2,4-9],
corticosteroids [1,2,10], antidepressants [4,8,11,12] and
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article, unless otherwise stated.Vitamin D is a secosteroid hormone that has many
skeletal and nonskeletal functions [18-94]. In addition to
its classic action on bone metabolism and osteoporosis
[18,19], its links and roles in relation to other diseases
have been addressed in the literature (diabetes mellitus
[18,20-23], hypertension [24,25], cardiovascular diseases
[18,26-29], multiple sclerosis [30-35], neurodegenerative
diseases [36-39], neuropsychiatric diseases [39-44], inflam-
matory bowel disease [33,45-49], dermatologic diseases
[50-58], rheumatoid arthritis [47,53,59-61], systemic lupus
erythematosus [60,62-67], transplant rejection [68-70],
cancer [18,52,68,71-73], postherpetic neuralgia [74], cor-
neal neuralgia [75], respiratory diseases [76-79], pregnancyioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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migraine headache [86], chronic low back pain [87,88],
chronic painful conditions and fibromyalgia [89,90] and
diabetic neuropathy [91-93]). Studies that have shed light
on areas that have given us the scientific underpinning for
our present proposal are described below.
1. Vitamin D has been called a neurosteroid hormone
[39,74,94-109], given its protective role against
neurotoxicity and detoxification pathways
[74,94,96-108] and also its receptors in different
parts of the central nervous system
[36,94-96,106-114].
2. Vitamin D receptors are present in the spinal cord,
nerve roots, dorsal root ganglia and glial cells
[94,96,97,113,115-118].
3. Vitamin D receptor gene polymorphism has a role
in the development of lumbar disc degeneration and
herniation [119-123].
4. Discs are composed largely of avascular tissue with
a great sensitivity to its nutritional supply and
excretion of waste products, and the balance
between these two processes is an important factor
that could lead to disc degeneration [124-127]. The
effects of active vitamin D metabolites in nucleus
pulposus and annulus fibrosus cells have been
studied [128]. Vitamin D inhibits and decreases
production of monocyte chemoattractant protein 1,
thrombopoietin, vascular endothelial growth factor
and angiogenin by human annulus cells in vitro
[129]. As mentioned above, vitamin D affects
detoxification pathways which are of importance in
disc cell nutritional balance.
5. Vitamin D possesses immune regulatory properties
which can downregulate proinflammatory cytokines
and upregulate anti-inflammatory cytokines
[22,32,36,46-48,58,67,70,74,78,90,94,96,130-146].
6. Vitamin D has properties that defend against cell
injury caused via free radicals, reactive oxygen
species, glutathione and glutamate
[74,94,96-108,136,147-149].
7. Vitamin D has a role in pain by downregulating
inflammatory cytokines that produce pain (a)
directly, (b) by stimulating release of pain
mediators, (c) by upregulating anti-inflammatory
cytokines to help the body combat inflammation,
(d) by its role in eliminating toxic metabolites or
(e) by increasing the antioxidant pool. It also
affects sensory neurons to modulate pain [114],
influences neuron excitability [96] and acts at the
level of substantia gelatinosa and spinal ganglion
in the process of sensory perception [118]. In
addition, its status affects pain sensitivity and
opiate activity [150].8. The role of the vitamin D receptor in skeletal
muscles [151-155] and its effects on muscle strength
and function have been identified [156-159].
In addition to the information described above, many
studies about changes that occur in LDH have been done,
as outlined below.
1. The contribution of inflammatory cytokines in the
pathogenesis of LDH has been widely addressed in
the literature. The herniated nucleus pulposus,
either with immunogenic properties itself or by
inducing an immunologic response in the nerve
roots, dorsal root ganglia and surrounding muscles,
is the starting point for the cascade of inflammation
initiated through immune cell activation and
infiltration and cytokine release [160-184].
2. Neuropathic pain involves the activation of neurons,
glial cells and the immune system [185,186]. Dorsal
root ganglia and dorsal roots play important roles in
LDH, not only by the effect of released
inflammatory cytokines but also by actively
amplifying inflammation by producing
proinflammatory cytokines and pain mediators that
affect pain perception and nociception. Among these
substances is brain-derived neurotrophic factor. Its
receptor has been identified in intervertebral
discs, with its expression being increased during
inflammatory conditions such as LDH and its
neuroimmunomodulatory role in the dorsal root of
the spinal cord [185,187-204]. The other factor is
glial cell–derived neurotrophic factor (GDNF). It has
been shown that GDNF reduces neuropathic pain
states [188,190,205-208]. Interestingly, vitamin D
affects neuropathic pain by directly suppressing
inducible nitric oxide that is expressed in glial cells
[96,136] or by affecting other substances, such as
reactive oxygen species or glutamate. Given the
immunomodulatory action of vitamin D, it is
possible that it could downregulate inflammatory
chemokines released by glial cells
[96,185-189,209-215]. It has been suggested that
vitamin D attenuates ischemia-induced brain injury
that is thought to be mediated through upregulation
of GDNF, in addition to its role in nitric oxide (NO)
suppression [216]. The results of other studies
support the hypothesis that GDNF is upregulated by
vitamin D [90,94,96,190,217]. Interleukin 6 (IL-6)
and tumor necrosis factor α produced by glial cells
were shown to be downregulated by vitamin D
[94,96,136], as were glial cell release of NO
[188,218,219], prostaglandin [188], IL-1 and IL-6
[218], which, as described below, could be
suppressed by vitamin D administration. Glial cells
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process of nociception [220-224]. Therefore, vitamin
D, through its immunoregulatory properties, affects
another important cell population that is inflamed
in disc herniation, either through suppressing
neurotoxic agents or by its action on neurotrophins.
Some specific inflammatory cytokines and pain media-
tors that are involved in LDH and vitamin D immuno-
modulatory effects with regard to these specific substances
are described in Table 1.
3. Detailed study of inflammatory cytokines and
subsequent pain mediators released in LDH has
shown that there is a shift toward type 1 T-helper
cell activity [164,177,181,182,228].
4. Vitamin D decreases the number and function of
type 1 T-helper cells [47,48,67,90,253].
5. Muscle changes associated with low back pain have
been studied [254-258]. Studies have shown how
muscles are affected by LDH [259-266]. Atrophy of
type II muscle fibers [259-261,263] or atrophy of
both types I and II muscle fibers [260] and adipocyte
enlargement are examples of how muscles are
targeted by LDH [264]. Vitamin D deficiency–
associated histochemical changes in muscles
somehow resemble those seen in LDH-affectedTable 1 Vitamin D effects on substances involved in
lumbar disc herniation
Vitamin D actions [references] LDH [references]
IFN-γ: D [46,65,72,88,94,144] E [160,171,179,180]
IL-1: D [46,65,72] E [173,225-227]
IL-2: D [46,65,72,88,92,94,139]
IL-4: D [46] E [179]
IL-5: D [67]
IL-6: D [32,46,72,92,94,136,141] E [165,176,181,228-230]
IL-8 E [164,225,231]
IL-10: U [32,47,67,74,90,94,96,144,226,227]
IL-12: D [22,32,67,139,140] E [181,182]
IL-17: D [47,90] E [181]
MCP: I [129] E [164,175]
MMP: I [232-240] E [176,190,228,241-243]
ROS: I [98,101,102,106,238] E [244]
NO: I [245] E [126,148,176,190,228,246-249]
Glutamate: I [101,147] E [220,221]
Glutathione: I [96,106,148]
PG: I [250] E [176,190,228,243,251,252]
D, Downregulation; E, Expression; I, Inhibition; IFN-γ, Interferon γ; IL, Interleukin;
LDH, Lumbar disc herniation; MCP, Monocyte chemoattractant protein; MMP,
Matrix metalloproteinase; NO, Nitric oxide; PG, Prostaglandin; ROS, Reactive
oxygen species; U, Upregulation.muscles with atrophy of type II muscle fibers
[267-271] and enlarged interfibrillar spaces and fat
infiltration and glycogen granules [271-274].
Another interesting aspect of vitamin D deficiency is
how it promotes skeletal muscle hypersensitivity
and sensory hyperinnervation [275]. Vitamin D
supplementation was shown to increase the diameter
of type II muscle fibers [181,276]. It also influences
transdifferentiation of muscle cells to adipose cells
[277]. With regard to the presence of vitamin D
receptor in skeletal muscles [151-155], its effect on
muscle growth and proliferation [278-282] and the
changes seen in muscles after LDH, we propose that
vitamin D supplementation also influences muscle
changes in this condition.
Methods/Design
Design of the study
We will conduct a randomized, placebo-controlled, double-
blind clinical trial.
Statement of ethical approval
This study was approved by the local research ethics
committee of Shiraz University of Medical Sciences,
Shiraz, Iran (CT-P-92-6632).
Informed consent
Informed consent will be obtained from all participants.
Setting
We will recruit patients who have appointments at the
neurosurgery outpatient departments of the university-
affiliated hospitals of Shiraz, Iran.
Participants
We will recruit 380 patients with LDH proven by phy-
sical examination and confirmed by magnetic resonance
imaging.
Intervention
Patients in the intervention arm will receive single-dose
intramuscular injections of 300,000 IU of vitamin D3
(1 ml). Individuals will be informed about the nature
of this study.
Inclusion criteria
The following are the inclusion criteria:
1. Single-level LDH
2. No coexistent or preexisting spine pathology (for
example, spondylolysis, spondylolisthesis, infection,
tumors, fracture)
3. Discogenic pain duration less than 8 weeks from
onset to physician’s evaluation
Sedighi and Haghnegahdar Trials 2014, 15:373 Page 4 of 11
http://www.trialsjournal.com/content/15/1/3734. Compliance with the study protocol
5. Normal laboratory studies that do not contraindicate
vitamin D3 injection
Exclusion criteria
The following are the exclusion criteria:
1. Daily supplementation of more than 800 IU of
vitamin D3
2. Serum calcium level above 10.5 mg/dl
3. Hypercalciuria (spot urine calcium/creatinine ratio
above 0.4)
4. Lymphoma, sarcoidosis, tuberculosis (TB),
hyperparathyroidism, celiac disease or malabsorption
syndromes
5. History of kidney stones
6. History of inflammatory back pain
7. Impaired renal function tests (glomerular filtration
rate less than 30 ml/min/1.73 m2)
8. Impaired hepatic function tests
9. Abnormal serum phosphorus, alkaline phosphatase
and parathyroid hormone values
10. Fasting blood sugar above 126 mg/dl
11. Previous spine surgery
12. History of trauma
13. Taking anticonvulsant, anti-TB medications or
vitamin D3 analogues
14. Cauda equine syndrome that requires emergency
surgical decompression
Laboratory Assessments
The following laboratory workups will be performed for
all included participants: serum 25-hydroxy vitamin D3
level, serum calcium, serum phosphorus, alkaline phos-
phatase, parathyroid hormone, liver function tests
(bilirubin (direct and total), alanine transaminase, aspar-
tate transaminase, total protein, total albumin), blood urea
nitrogen, creatinine, spot urine for calcium and fasting
blood sugar. Clinic-based pre-intervention interviews and
physical examinations will include the following:
1. McGill Pain Questionnaire: The McGill Pain
Questionnaire is used to evaluate different pain
qualities and intensities. This questionnaire
consists of four major descriptors: sensory,
affective, evaluative and miscellaneous. Each
descriptor has its own rank value. The sum of
these rank values is the pain rating index. Present
pain intensity is measured on scale from 0 to
5 [281].
2. Visual analogue scale (VAS) to evaluate low back
pain and radicular pain: A VAS is a pain
measurement scale that incorporates numbers
and faces to depict the severity of pain. It isusually a 100-mm line. Its ends show the pain
extremes [229,282].
3. A physical examination to detect any sensory deficits.
Randomization
Patients will be categorized on the basis of their serum
25-hydroxy vitamin D3 levels into three groups:
 Group 1: Optimum 25-hydroxy vitamin D3 level
(32 to 50 ng/ml)
 Group 2: Deficient 25-hydroxy vitamin D3 level
(less than 10 ng/ml)
 Group 3: Insufficient 25-hydroxy vitamin D3 level
(less than 32 ng/ml)
Each of the groups will be randomized, based on ran-
domly computer-generated numbers, into two groups to
receive intramuscular injection of either 300,000 IU of
vitamin D3 (1 ml) or distilled water (1 ml). All patients
will be prescribed daily 15 mg Meloxicam capsules. Our
study population will be warned verbally and in writing
about the potential for severe adverse side effects of vita-
min D3 (nausea, vomiting, abdominal pain, metallic taste,
breathing difficulties). They will have access to emergency
department care should side effects occur.
The study will last 15 days. After vitamin D3 injection,
patients will be contacted by telephone every 3 days to
assess the sensory and pain effects of vitamin D3 with
the McGill Pain Questionnaire and the VAS (a total of
five times). Participants will be provided with the VAS so
that they can look at the scale and report their pain se-
verity during the telephone interviews.
The following are the final post-treatment evaluations
that will be carried out at the clinic:
1. McGill Pain Questionnaire
2. VAS (for low back pain and radicular pain)
3. Physical examination to detect any sensory deficits
Post-treatment 25-hydroxy vitamin D3 levels (after 15
days) will be measured for those participants who have
received vitamin D3 (N = 190).
Statistical analysis
Data will be assessed by analysis of variance and paired
tests.
Discussion
On the basis of the inflammatory nature of disc hernia-
tion and the immunomodulatory effects of vitamin D, as
well as the existence of vitamin D receptors in various
parts of areas that are affected in the process of disc
herniation, we propose a novel role for vitamin D in the
treatment of discogenic pain and sensory deficits related
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a role in reducing the severity of discogenic pain and
that vitamin D3 can improve discogenic-related sensory
deficits.
The following are our general objectives in this trial:
1. Effect of vitamin D3 on discogenic pain
2. Effect of vitamin D3 on discogenic sensory deficits
3. Effect of posttreatment 25-hydroxy vitamin D3 level
on pain and sensory deficit severity
4. Determining a cut-off level of 25-hydroxy vitamin D3
that is efficient in improving pain and sensory
deficits
The following are our applicative objectives:
1. Proposing vitamin D3 as part of medical treatment
for LDH
2. Improving LDH patients’ quality of life
3. Decreasing the economic and health burden of LDH
Our ultimate goal in this study is to introduce a new
treatment strategy for the treatment of discogenic pain.
Trial status
The study protocol has been approved by the Vice-
Chancellor for Research of Shiraz University for Medical
Sciences. Recruitment has not been initiated.
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